Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials
Background: New randomized, controlled trials have become available on oral P2Y12
inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing …
inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing …
Safety and Effectiveness of Contemporary P2Y12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population‐Based Cohort …
JE Yun, YJ Kim, JJ Park, S Kim, K Park… - Journal of the …, 2019 - Am Heart Assoc
Background Prior reports indicate that the effect of P2Y12 inhibitors may be different in East
Asian patients (“East Asian paradox”); therefore, understanding the outcomes associated …
Asian patients (“East Asian paradox”); therefore, understanding the outcomes associated …
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary …
U Zeymer, P Widimsky, N Danchin… - European Heart …, 2016 - academic.oup.com
Aims Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70%
of patients admitted with acute coronary syndromes in clinical practice. This study provides a …
of patients admitted with acute coronary syndromes in clinical practice. This study provides a …
Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non–ST-elevation acute coronary syndrome
C Bavishi, S Panwar, FH Messerli… - The American journal of …, 2015 - Elsevier
Newer oral P2Y 12 inhibitors are more potent and have faster onset of action than
clopidogrel. However, the efficacy and safety in patients with non–ST-elevation acute …
clopidogrel. However, the efficacy and safety in patients with non–ST-elevation acute …
Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 …
Z Motovska, O Hlinomaz, R Miklik, M Hromadka… - Circulation, 2016 - Am Heart Assoc
Background: No randomized head-to-head comparison of the efficacy and safety of
ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these …
ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these …
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome–randomized, double-blind, phase III PHILO study–
S Goto, CH Huang, SJ Park, H Emanuelsson… - Circulation …, 2015 - jstage.jst.go.jp
Background: Few data on the relative efficacy and safety of new P2Y 12 inhibitors such as
prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute …
prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute …
Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI
D Capodanno, DJ Angiolillo - Cardiovascular Interventions, 2023 - jacc.org
Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and …
BACKGROUND: Antiplatelet therapy is essential treatment for acute coronary syndromes
(ACS). Current therapies, however, have important limitations affecting their clinical success …
(ACS). Current therapies, however, have important limitations affecting their clinical success …
Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
Prasugrel is a new P2Y 12 receptor antagonist that has been investigated for the treatment
of atherothrombosis in patients with cardiovascular disease undergoing percutaneous …
of atherothrombosis in patients with cardiovascular disease undergoing percutaneous …
相关搜索
- patients with acute coronary syndromes
- p2y12 inhibitors meta analysis
- safety of oral p2y12 inhibitors
- newer oral p2y12 inhibitors
- p2y12 inhibitors prasugrel or ticagrelor
- p2y12 inhibitors clopidogrel in patients
- potent p2y12 inhibitor therapy
- p2y12 inhibitors st elevation
- p2y12 inhibitors safety and effectiveness
- patients with acute myocardial infarction
- p2y12 receptor inhibitors in patients
- receptor inhibitors benefits and pitfalls
- receptor inhibitors antiplatelet therapy
- management of acute coronary syndromes
- meta analysis prasugrel or ticagrelor
- meta analysis clopidogrel in patients